← Eichor
Condition: Hematological Patients Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hematological Patients

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

IASO-782 in Autoimmune Hematological Diseases
Phase 1 · 2 location(s) · Shanghai IASO Biotechnology Co., Ltd · NCT06534021Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematologi
Phase N/A · 5 location(s) · Medical University Innsbruck · NCT06821880The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT
Phase 1 · 1 location(s) · Anhui Provincial Hospital · NCT06558253Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
NA · 1 location(s) · Zhejiang Cancer Hospital · NCT07670949Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04195633Distraction With Virtual Reality From Pain and Anxiety for Patients With Hematological Malignancies
NA · 1 location(s) · Yesmine Amara · NCT07085065APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU
NA · 1 location(s) · Centre Hospitalier Régional Metz-Thionville · NCT05475600Validation of Hematological Indices
NA · 1 location(s) · Petrovsky National Research Centre of Surgery · NCT06476171Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Phase 3 · 106 location(s) · Kura Oncology, Inc. · NCT07007312Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Phase 3 · 11 location(s) · Lakefront Biotherapeutics NV · NCT06652633An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in
Phase 1 · 1 location(s) · Shanghai Yuyao Biotech Co., Ltd. · NCT06225856Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies
NA · 4 location(s) · University Hospital, Limoges · NCT06150469Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT07189117CD4CAR for CD4+ Leukemia and Lymphoma
Phase 1 · 6 location(s) · Huda Salman · NCT03829540The Endothelial Cell Dysfunction and Outcome Project for Hematological Neoplasms
Phase N/A · 1 location(s) · Prof. Dr. Thomas Luft · NCT05502887Covid-19 in Hematological Malignancies
Phase N/A · 6 location(s) · Sorveglianza Epidemiologica Infezioni Fungine Emopatie Malig · NCT04733729The Study of ICP-248 in Patients With Mature B-cell Malignancies
Phase 1 · 22 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT05728658Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients Wit
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07135778Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemo
NA · 10 location(s) · University Hospital, Angers · NCT06409767Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT04290000RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06125483HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relaps
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05751044A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Phase 1 · 1 location(s) · Nanjing Chia-tai Tianqing Pharmaceutical · NCT06049667Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological
Phase 1 · 4 location(s) · Acrotech Biopharma Inc. · NCT07036133T-cell Developmental Status in Patients With Malignant Hematological Tumors
Phase N/A · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT07035938HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Rela
Phase 1/Phase 2 · 33 location(s) · Princess Maxima Center for Pediatric Oncology · NCT05745714Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
Phase 3 · 1 location(s) · Anhui Provincial Hospital · NCT07047456TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06206174The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NA · 1 location(s) · Hebei Senlang Biotechnology Inc., Ltd. · NCT05618041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.